Lancet published the latest results to Bimagrumab from Novartis in the RESILIENT study.
Between Sept 26, 2013, and Jan 6, 2016, 251 participants were enrolled to the study, of whom 63 were assigned to each bimagrumab group and 62 were allocated to the placebo group.
For more Details visit Lancet
Clinical Trials
Bimagrumab
News about Myositis
3 replies on “Safety and efficacy of intravenous bimagrumab in inclusion body myositis”
👍 hopeful
are Bimagrumab already available
Hello Hanna,
no Bimagrumab is in clinical development at Novartis and is not yet available on market. The antibody was developed by MorphoSys in Munich.
Activin type II receptors are intended for the treatment of muscle disorders associated with muscle atrophy.
#BYM338